Longeveron Inc - LGVN Net Assets per Single Share

Graphic logo of Longeveron Corp (LGVN)

Longeveron Inc. develops cellular anti-aging therapies, promising stable demand and high margins. The book value per share history demonstrates capital dynamics, where the 3.30 metric serves as the target level. Active R&D in the field of Alzheimer's disease is complemented by a production and logistics outsourcing strategy to optimize operational processes.

Longeveron Corporation - LGVN Net Assets per Share (period 07/04/2022 - 10/28/2026)

longeveron.com - analytical breakdowns and key metrics (LGVN)

- price and consensus price forecast:
Stock Quotes Longeveron Corp|LGVN - Price Target Chart
- market capitalization data:
Market Value Longeveron Inc.|LGVN - Business Value
- book capitalization data:
Net Assets per Single Share Longeveron|LGVN - Book Valuation of Business|Market Cap to Net Assets Ratio longeveron.com|LGVN - Aggregate Business Assets
- debt and liquidity data:
Total Debt to Capital Longeveron Inc.|LGVN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Longeveron|LGVN - Company Total Debt|Debts to Book Capitalization Longeveron Inc.
Analysis of all company metrics:Longeveron Corp - LGVN
Finished products of Longeveron

The book value per share, which stands at 3.30, determines the portion of net assets attributable to a single security and serves as an indicator of the asset-backed protection of investor capital. The dynamics of equity per share reflect the capitalization rate of Longeveron Inc. (LGVN), where growth in this metric confirms the company's financial stability during critical clinical trials of Alzheimer's disease therapies.

Competitors of Longeveron Inc. (LGVN)

MESO - Accounting Value per Share|LCTX: Net Assets per Single Share|Net Assets per Single Share Surrozen, Inc.|CCEL (Cryo-Cell International, Inc.) - Equity per Share|FBLG: Net Assets per Single Share|Net Assets per Share BioRestorative (BRTX)|Accounting Value per Share Creative Medical Technology